IMMUNIC, INC. — Director's Dealing 2024

Mar 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2024-03-04

Reporting Person: Muehler Andreas (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-04	Stock Option	$10.73	D	100000	Disposed	2032-01-03	Common Stock (100000)	Direct
2024-03-04	Stock Option	$3.40	D	10000	Disposed	2032-06-15	Common Stock (10000)	Direct
2024-03-04	Stock Option	$15.72	D	65000	Disposed	2031-03-01	Common Stock (65000)	Direct
2024-03-04	Stock Option	$12.30	D	44000	Disposed	2030-07-01	Common Stock (44000)	Direct
2024-03-04	Stock Option	$13.34	D	10000	Disposed	2029-08-12	Common Stock (10000)	Direct
2024-03-04	Stock Option	$13.29	D	30000	Disposed	2029-08-01	Common Stock (30000)	Direct
2024-03-04	Stock Option	$1.72	A	259000	Acquired		Common Stock (259000)	Direct

Footnotes

F1: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.